Remove 2014 Remove Documentation Remove Drug Pricing
article thumbnail

Exforge antitrust settlement caps Novartis’ year of legal disputes

Pharmaceutical Technology

The agreement outlined that Par would keep its generic equivalent off the market for as many as two years, delaying the generic launch till September 30, 2014. At the centre of the case was Gilenya’s ‘405 patent, which details methods for treating relapsing multiple sclerosis with a specific dosage of the drug.

article thumbnail

The unsustainability of clinical trials and need for transformative change

Pharmaceutical Technology

According to a November 2024 GlobalData report, per-trial costs have risen steadily since 2014, with single country trials increasing by 2.9% 9 Rising direct trial costs and lost revenue due to delayed approval are key factors driving the total cost of bringing a new drug to market to a staggering $2.3bn. per year over this decade.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How do you solve a problem like Bedoya?

Ramblings of a pharmacist

Starting salaries have dropped dramatically since I started pharmacy school in 2014. These fees, as documented by CMS, have increased by 109,000% in the past 10 years. Scratch that - the plight of the community pharmacist at chains and indies and grocery stores seems to get worse all the time.

article thumbnail

Pricing, Profits and Progress: Pharma’s Post-COVID Priorities

pharmaphorum

Against this backdrop, there has been substantial public debate about rising drug prices forced on consumers, including the trite notion that pharmaceutical companies are being “greedy” and seeking to price-gouge the public. The truth about rising drug prices is more nuanced and merits exploration.